Market News & Trends
CG Oncology Completes Enrollment in PIVOT-006
CG Oncology, Inc. recently announced it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following…
BirchBioMed Announces Hamilton Health Sciences’ Centre for Burn Research in Ontario as First Clinical Trial Site for Pioneering Burns Scar Treatment
BirchBioMed Inc. recently announced Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario, Canada, as the first contracted clinical trial site for its Phase…
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Medicus Pharma Ltd., a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, and Antev Limited, a…
Quotient Sciences & CPI to Accelerate RNA Drug Development With Joint Venture
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form…
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Propanc Biopharma, Inc. recently announced a plan to acquire $100 million of Ethereum over the next 12 months. The asset purchase of Ethereum will enhance…
Olema Oncology Announces New Clinical Trial Agreement With Pfizer
Olema Pharmaceuticals, Inc. recently announced a new clinical trial collaboration and supply agreement with Pfizer Inc. in metastatic breast cancer. The companies will evaluate in…
Zenas BioPharma & Royalty Pharma Enter Obexelimab Funding Agreement for up to $300 Million
Zenas BioPharma, Inc. and Royalty Pharma plc recently announced Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on…
Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy Designation Granted by FDA for ETX101 in SCN1A+ Dravet Syndrome
Encoded Therapeutics Inc. recently announced the US FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ETX101 following review of preliminary seizure data from…
Step Pharma Announces First Participant Dosed in a Phase 1b Trial of Dencatistat for Essential Thrombocythaemia
Step Pharma recently announced the first participant has been dosed with its lead asset dencatistat in a phase 1b clinical trial for essential thrombocythaemia (ET).…
OMass Therapeutics Enters Exclusive Collaboration & License Agreement With Genentech
OMass Therapeutics recently announced it has entered into an exclusive collaboration and license agreement with Genentech for the rights to develop and commercialize OMass’ preclinical…
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure & Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75
Lexicon Pharmaceuticals, Inc. recently announced a post-hoc analysis (Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF) of clinical data was…
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Esperion welcomed the inclusion of bempedoic acid as the only non-statin newly recommended for LDL-C lowering and cardiovascular risk reduction in the 2025 Focused Update…
Common Intracellular Toxin Could Help Fight Leukemia
All cells naturally produce formaldehyde as a byproduct of metabolism. To survive this toxic stress, both healthy and cancerous blood-forming cells rely on a built-in…
TOLREMO Therapeutics Receives Two FDA Fast Track Designations
TOLREMO therapeutics AG recently announced its lead candidate, TT125-802, received two Fast Track designations from the US FDA for the treatment of non-small cell lung…
Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy
Wugen, Inc. recently announced the closing of $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital,…
TREOS Bio Partners With Charité Berlin & Junshi Biosciences to Launch Pivotal Phase 2 Clinical Trial in Refractory MSS Colorectal Cancer
TREOS Bio Ltd. recently announced the execution of clinical collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences for the initiation of OBERTO-202, a…
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
MannKind Corporation recently announced United Therapeutics Corporation has exercised its option—granted under the companies’ 2018 license and collaboration agreement—to develop a second dry powder inhalation…
Moleculin Issues New Positive AML Overall Survival Data
Moleculin Biotech, Inc. recently announced the completion of its Phase 1B/2 (MB-106) clinical trial evaluating Annamycin in combination with Cytarabine (also known as Ara-C and…
Bio-Rad Expands Range of StarBright Dyes to Enhance Panel Design Capabilities for Spectral Flow Cytometry
Bio-Rad Laboratories, Inc. recently announced the introduction of a new range of StarBright Dyes, providing greater choice and flexibility for spectral flow cytometry in immunology…
Cereno Scientific Granted FDA Fast Track Designation for CS1 in Rare Disease Pulmonary Arterial Hypertension
Cereno Scientific recently announced the US FDA has granted Fast Track designation to its lead program, CS1, for the treatment of pulmonary arterial hypertension (PAH).…